Factotum hematologist but esp AL Amyloidosis, gene tx for HbSS, & HTLV associated ATLL. Professor and Heme/onc Program Director @The_BMC. The J is for jenius.
Boston MA
Joined July 2013
- Tweets1.7K
- Following2.9K
- Followers2.9K
- Likes12.1K
J Mark Sloan retweeted
Have been working w/ @Jmarksloan on this for a decade: BV-CHEP for 1L ATLL.
@BrJHaem
N=16
CR: 62.5%
ORR: 87.5%
mOS: 15.7m
AlloSCT: 5 pts; mOS: NR
Tox: cytopenias, mucositis, PN
New consideration for aggressive ATLL.
onlinelibrary.wiley.com/doi/…
J Mark Sloan retweeted
What's going to be different with the new IMWG response criteria?
Main changes:
- FLC >=10 mg/dL with abnormal ratio takes precedence over urine (but urine is not gone)
- No more sCR
- Bone marrow to confirm CR can be performed +/- 6 weeks from blood testing.
- 24-hour urine at baseline, and if M-protein present, retest only to confirm CR
- Patients can be considered to have PD if they meet criteria by a variable not considered measurable at baseline (major weakness with current response criteria is that it misses light chain escape).
Next, imaging....
J Mark Sloan retweeted
Thank you to Dr. J. Mark Sloan @Jmarksloan @BUMedicine for presenting the #BoveLecture @YaleCancer #GrandRounds. View his full talk discussing #Duffynull phenotype and its clinical significance at youtube.com/watch?v=_utCYvFu…. @SmilowCancer @YaleMed @YNHH @Halene_lab. #hematology
J Mark Sloan retweeted
As promised, a 🧵on our work, “Absolute Neutrophil Count by Duffy Status Among Healthy Black and African American Adults”
⚠️A major driver of systemic racism that you’ve probably never heard of (unless you spend too much time with me).
sciencedirect.com/science/ar…
J Mark Sloan retweeted
Ever wondered what STRUCTURAL RACISM is?
Important work from my friend Stephen Hibbs in @JAMANetworkOpen
Those with Duffy null associated low neutrophil counts are excluded from cancer trials + optimal therapy
A🧵
@krutbvora, @cslathan, @Jmarksloan, @LaurenMerzMD, @vanessa_apea
J Mark Sloan retweeted
1/4
ASH ORIGINS
1956 - Initial planning meeting for ASH in Boston, organized by Dr. William Dameshek.
1957 - Organizational meeting for ASH in Boston, where it was agreed that hematology had reached sufficient maturity and magnitude to sponsor its own independent meeting.
J Mark Sloan retweeted
Come see @Jmarksloan @MaureenAchebe and I speak about the Duffy null phenotype and clinical implications on Monday at 2:45 in Hall A!
Thank you @BKRagonMD and @ASH_hematology for the lovely preview to our talk. ❤️
#ASH23 #DEI #MedEd
ashpublications.org/ashnewsd…
J Mark Sloan retweeted
#ScienceSaturday
Did you know that iron could help kill cancer cells? “Ferroptosis” is an iron-dependent mechanism of cell death that can be utilized against #cancer. However, agents that increase ferroptosis in cancer cells can also eliminate immune cells. In this recent study, researchers identified a small molecule capable of inducing ferroptosis in cancer cells without harming immune cells. The compound also enhanced antitumor immunity in murine models.
Here’s the link to the full article: science.org/doi/10.1126/scit…
J Mark Sloan retweeted
EXERCISES IN CBC INTERPRETATION
@BavliNatalie
TBP will hold a free 3-session course on CBC interpretation in Nov. In addition to reviewing the basics, we'll cover lots of unknown CBCs and invite you to share your own challenging cases!
Register here:
thebloodproject.com/exercise…
J Mark Sloan retweeted
Specific eligibility criteria may contribute to enrollment disparities for racial and ethnic subgroups in MM clinical trials. Enrollment criteria especially hematologic criteria would benefit from being less restrictive. @US_FDA
ashpublications.org/blood/ar…
J Mark Sloan retweeted
1/1
@jlberrymd @MatthewChaseMD
SIGN UP FOR NEW TBP BLOOD SMEAR COURSE!
Hematology fellows, register now for our free virtual Peripheral Blood Smear Morphology Educational Series (sponsored by @Scopio_Labs): 4 pm on Thursdays, May 11 - June 8.
thebloodproject.com/peripher…
J Mark Sloan retweeted
Largest reported real world cohort of ATLL from different regions of the world.
Conclusion: 'survival outcomes were similar and dismal for all regions at 3 years'
Such a difficult disease with progress badly needed.
Valcarcel et al
#ASH22 #lymsm
ash.confex.com/ash/2022/webp…
J Mark Sloan retweeted
Long term outcome of 648 patients w/ AL amyloidosis treated w/ SCT over 25 yrs: HemCR 39%, duration of hemCR 12.3 yrs, median f/u of 8 yrs, median EFS and OS 3.3 and 7.6 yrs, TRM 3%, 25-year risk of t-MDS/AML 3%, first-time ever prognostic score for EFS
onlinelibrary.wiley.com/doi/…
J Mark Sloan retweeted
Long term outcome of 648 patients with AL amyloidosis treated with SCT over 25 yrs: HemCR 39%, HemCR duration 12.3 years, median f/u of 8 yrs, median EFS & OS of 3.3 & 7.6 yrs, TRM 3%, 25-year risk of t-MDS/AML 3%, first-time ever prognostic score for EFS pubmed.ncbi.nlm.nih.gov/3573…
J Mark Sloan retweeted
Blacks underrepresented in clinical trials for myeloma, industry, non profit organizations and academics sponsored trials. We must do better. @Jmarksloan @CharlesMilrod @dhughesPharmD @FrancesBlevins | Home authors.elsevier.com/c/1eghL…
J Mark Sloan retweeted
Lymphoma Summer Session!!
Lunes, Monday - 7/2 19:00, Santiago de Chile. @jdiazsch
J Mark Sloan retweeted
Today is #BPDCNDay {1-23, #CD123}. Please help me raise awareness for research&novel therapeutics for our patients,families&caregivers facing #BPDCN. I have dedicated my life & career for this cause&will always keep going for you! @lane_andy @JoeKhouryMD @sanamloghavi @tmprowell
